|
|
|
|
|
|
|
|
Current Oncology
Commentary
Have we given up on a cure for ovarian cancer?
A Countercurrents Seriesa
S.A. Narod , MD *
* Women’s College Research Institute, Women’s College Hospital, Toronto, ON.
doi: http://dx.doi.org/10.3747/co.22.2517
In December 2014, on the
force Web site, executive director Sue Friedman, heralded a game-changing holiday gift for people with
BRCA
mutations: “Today is a landmark for the
hboc
[hereditary breast and ovarian cancer] community”1. In an accompanying article 2, Lisa Rezende wrote about the U.S. Food and Drug Administration (
fda
) decision to approve olaparib for the treatment of recurrent ovarian cancer in women with a
BRCA1
or
BRCA2
mutation:.......
REFERENCES
1. Friedman S. A
Game-Changing Holiday Gift for People with BRCA Mutations [blog post].
Tampa, FL: Facing Our Risk of Cancer Empowered (force); 2014. [Available at: http://www.facingourrisk.org/get-involved/HBOC-community/BRCAHBOC-blogs/FORCE/uncategorized/a-game-changing-holiday-gift-for-people-with-brca-mutations/; cited 17 April 2015]
2. Rezende L. FDA
Approves the First PARP Inhibitor for Treatment of Ovarian Cancer in
BRCA Mutation Carriers [Web page]. Tampa, FL: Facing Our Risk of Cancer
Empowered (force); 2014. [Available at: http://www.facingourrisk.org/research-clinical-trials/research-findings/lynparza.php; cited 17 April 2015]
3. Ledermann J, Harter
P, Gourley C, et al. Olaparib maintenance therapy in patients with
platinum-sensitive relapsed serous ovarian cancer: a preplanned
retrospective analysis of outcomes by BRCA status in a randomised phase 2
trial. Lancet Oncol 2014;15:852–61.
4. Oza AM, Cibula D,
Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent
platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet
Oncol 2015;16:87–97.
5. McLaughlin JR,
Rosen B, Moody J, et al. Long-term ovarian cancer survival associated
with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013;105:141–8.
6. Venook AP,
Tabernero J. Progression-free survival: helpful biomarker or clinically
meaningless end point? J Clin Oncol 2015;33:4–6.
7. Secord AA, Barnett
JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target parp inhibitor use in platinum-sensitive recurrent ovarian cancer. Int J Gynecol Cancer 2013;23:846–52.
8. Quested T. AZ lines up second Cambridge blockbuster drug. Business Weekly 2014; October 27:. [Available online at: http://www.businessweekly.co.uk/news/biomedtech/17728-az-lines-second-cambridge-blockbuster-drug; cited 27 April 2015]
9. Myriad Receives FDA Approval of BRACAnalysis cdx
as Companion Diagnostic for Lynparza (olaparib) in Ovarian Cancer
Patients [press release]. Salt Lake City, UT: Myriad Genetics; 19
December 2014. [Available online at: http://investor.myriad.com/releasedetail.cfm?releaseid=888523; cited 17 April 2015]
10. Byrski T, Dent R, Blecharz P, et al. Results of a phase ii
open-label, non-randomized trial of cisplatin chemotherapy in patients
with BRCA1-positive metastatic breast cancer. Breast Cancer Res
2012;14:R110.
11. Tutt A, Ellis P, Kilburn L, et al. The tnt trial: a randomized phase iii trial of carboplatin (c) compared with docetaxel (d) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (cruk/07/012)
[abstract S3-01]. In: Program and abstracts of the 2014 San Antonio
Breast Cancer Symposium; San Antonio, TX, U.S.A.; 9–13 December 2014.
[Available online at: http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L_789; cited 17 April 2015]
12. Burger RA, Brady
MF, Bookman MA, et al. on behalf of the Gynecologic Oncology Group.
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med 2011;365:2473–83.
13. Perren TJ, Swart AM, Pfisterer J, et al. on behalf of the icon 7 investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–96.
14. Nixon RM. Annual
Message to the Congress on the State of the Union. 22 January 1971. In:
Peters G, Woolley JT. The American Presidency Project [Web site]. Santa
Barbara, CA: The American Presidency Project; n.d. [Available at: http://www.presidency.ucsb.edu/ws/?pid=3110; cited 17 April 2015]
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.